

162. SCHEIN, P. S., COONEY, D. A. AND VERNON, M. L.: The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity. *Cancer Res.* 27: 2324, 1967.
163. SCHEIN, P. S. AND LOFTUS, S.: Streptozotocin: Depression of mouse liver pyridine nucleotides. *Cancer Res.* 28: 1501, 1968.
164. SCOTT, D. A.: Crystalline insulin. *Biochem. J.* 28: 1592, 1934.
165. SELIGSON, D. AND SELIGSON, H.: The conversion of alloxan to alloxanic acid in plasma. *J. Biol. Chem.* 190: 647, 1951.
166. SHIPLEY, E. AND BYER, K. H.: The effect of vagotomy and of thoracic sympathectomy on the blood glucose changes in dogs given alloxan. *Endocrinology* 40: 154, 1947.
167. SPEER, J. H. AND DABOVICH, T. C.: Alloxan. *Org. Syn.* 21: 5, 1941.
168. STEPHENS, S. AND LAZAROW, A.: The effect of methylene blue on established alloxan diabetes. *J. Lab. Clin. Med.* 36: 113, 1950.
169. STRECKER, A.: Notiz über eine eigenthümliche Oxydation durch Alloxan. *Ann. Chem.* 123: 363, 1862.
170. SOUTH SHORE ANALYTICAL AND RESEARCH LABORATORY, INC.: Toxicity studies on NSC 37917, streptozotocin, parts 2, 3, and 4. Special studies on the hyperglycemic action of streptozotocin. Report to the Cancer Chemotherapy National Service Center, May 21, 1962.
171. SOUTH SHORE ANALYTICAL AND RESEARCH LABORATORY, INC.: Studies on streptozotocin, NSC 85998, an Zedalan, NSC 85680. Report to the Cancer Chemotherapy National Service Center, May 25, 1965.
172. SOUTH SHORE ANALYTICAL AND RESEARCH LABORATORY, INC.: Toxicity studies on compound NSC 85998. Report to the Cancer Chemotherapy National Service Center, Jan. 26, 1966.
173. VEKLEB, R. I.: Alloxan destruction in blood of animals. *Biokhimiya* 21: 562, 1956.
174. VERNON, M. L. AND TUBING, T. W.: Ultrastructural studies of effects of streptozotocin. Temporal study in mice. U.S. Clearinghouse Report No. PB 177067, Dec. 27, 1967.
175. VOLLMER, E. P., CARBY, M. M., GOLDEN, R. G. AND GILMORE, J. W.: Prevention of alloxan diabetes by sodium nitrite and paraaminopropiophenone. *Science* 120: 944, 1954.
176. WAIBEREN, B. A.: Alloxan diabetes in mice. *Proc. Soc. Exp. Biol. Med.* 67: 154, 1948.
177. WATKINS, D., COOPERSTEIN, S. J. AND LAZAROW, A.: Alloxan distribution (*in vitro*) between cells and extracellular fluid. *Amer. J. Physiol.* 207: 431, 1964.
178. WEBB, J. L.: Alloxan. In *Enzyme and Metabolic Inhibitors*, ed. by J. L. Webb, vol. III, p. 367, Academic Press, New York, 1966.
179. WEINGLASS, A. R., FRANK, E. G. AND WILLIAMS, R. H.: Inhibition of diabetogenic action of alloxan. *Proc. Soc. Exp. Biol. Med.* 58: 216, 1945.
180. WEST, E. S. AND HIGHT, D. M.: Resistance of guinea pigs to action of alloxan. *Proc. Soc. Exp. Biol. Med.* 68: 60, 1948.
181. WIENER, H.: Über Zersetzung und Bildung der Harnsäure im Thierkörper. *Arch. Exp. Pathol. Pharmacol.* (Naudyn-Schmiedebergs) 42: 375, 1899.
182. WRENHALL, G. A., COLLIN-WILLIAMS, J. AND BEST, C. H.: Initial changes in the blood sugar of the fasted anesthetized dog after alloxan. *Amer. J. Physiol.* 166: 228, 1950.
183. WÖHLER, F. AND LIEBIG, VON J.: Untersuchungen über die Natur der Harnsäure. *Ann. Chem.* 26: 241, 1838.
184. YOUNG, F. G.: Permanent experimental diabetes produced by pituitary (anterior lobe) injections. *Lancet* 2: 372, 1937.

Statement of Ownership, Management and Circulation required by the Act of October 23, 1962; Section 4369, Title 39, United States Code.

1. *Date of Filing:* October 1, 1970.
2. *Title of Publication:* Pharmacological Reviews.
3. *Frequency of Issue:* Quarterly.
4. *Location of known Office of Publication:* 428 E. Preston St., Baltimore, Md. 21202.
5. *Location of the Headquarters or General Business Offices of Publisher:* 428 E. Preston St., Baltimore, Md. 21202.
6. *Publisher:* The Williams & Wilkins Company, 428 E. Preston St., Baltimore, Md. 21202.

*Editor:* Dr. Marion deV. Cotten, Medical College of Georgia, Augusta, Ga. 30902.

7. *Owners:* (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual, must be given.) American Society for Pharmacology and Experimental Therapeutics, Inc., 9650 Rockville Pike, Bethesda, Md. 20014. No stockholders.

8. *Known bondholders, mortgagees and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages or other securities are:* None.

9. Paragraphs 7 and 8 include, in cases where the stockholder or security holder appears upon the books of the company as trustee or in any other fiduciary relation, the name of the person or corporation for whom such trustee is acting, also the state-

ments in the two paragraphs show the affiant's full knowledge and belief as to the circumstances and conditions under which stockholders and security holders who do not appear upon the books of the company as trustees, hold stock and securities in a capacity other than that of a bona fide owner. Names and addresses of individuals who are stockholders of a corporation which itself is a stockholder or holder of bonds, mortgages or other securities of the publishing corporation have been included in Paragraphs 7 and 8 when the interests of such individuals are equivalent to 1 percent or more of the total amount of the stock or securities of the publishing corporation.

	(a)*	(b)†
10. A. Total No. Copies Printed (Net Press Run).....	4081	4138
B. Paid Circulation		
1. To term subscribers by mail, carrier delivery or by other means).....	2742	2980
2. Sales through agents, news dealers or otherwise.....	—	—
C. Free Distribution (including samples), by mail, carrier delivery or by other means.....	40	40
D. Total No. of copies distributed.....	2782	3020

\* Average no. of copies for each issue during preceding 12 months.

† Single issue nearest to filing date.

I certify that the statements made by me above are correct and complete. (Signed) Mary G. MacIsaac, Publisher.

## INDEX

### PHARMACOLOGICAL REVIEWS

Volume 22

1970

- Adhesion, influence on platelet function, 97  
Aggeler, Paul M. See O'Reilly and Aggeler, 35  
Aggregation, influence on platelet function, 97  
Anticoagulant drugs, oral; determinants of response in man, 35
- Beets, M. G. J. The molecular parameters of olfactory response, 1  
Brestkin, N. N. See Kabachnik, Brestkin, Godovikov, Michelson, Rozengart, and Rozengart, 355
- Calcium, role in release of neurotransmitter substances and hormones, 389  
Cholinesterases, hydrophobic areas on active surface, 355
- Diabetes produced by drug damage to insulin secreting cells, 485
- Drugs  
  damage to insulin secreting cells, 485  
  immunosuppressive, 189  
  oral anticoagulant; determinants of response in man, 35
- Godovikov, N. N. See Kabachnik, Brestkin, Godovikov, Michelson, Rozengart, and Rozengart, 355
- Hormones, role of calcium in release of, 389  
Hydrophobic areas, on active surface of cholinesterases, 355  
Hypertensive vessels, pharmacology of, 249
- Immunosuppressive drugs, 189  
Insulin secreting cells, drug damage producing diabetes, 485
- Kabachnik, M. I., A. P. Brestkin, N. N. Godovikov, M. J. Michelson, E. V. Rozengart, and V. I. Rozengart. Hydrophobic areas on the active surface of cholinesterases, 355
- Makinodan, T., G. W. Santos, and R. P. Quinn. Immunosuppressive drugs, 189  
McLean, Elizabeth K. The toxic actions of pyrrolizidine (Senecio) alkaloids, 429  
Michelson, M. J. See Kabachnik, Brestkin, Godovikov, Michelson, Rozengart, and Rozengart, 355  
Molecular parameters of olfactory response, 1  
Muscle, vascular smooth; pharmacology of normal and hypertensive vessels, 249  
Mustard, J. F., and M. A. Packham. Factors influencing platelet function: adhesion, release, and aggregation, 97
- Neurotransmitter substances, role of calcium in release of, 389
- Olfactory response, molecular parameters of, 1  
Oral anticoagulant drugs, determinants of the response in man, 35  
O'Reilly, Robert A., and Paul M. Aggeler. Determinants of the response to oral anticoagulant drugs in man, 35
- Packham, M. A. See Mustard and Packham, 97  
Platelet function, influence of adhesion, release, and aggregation, 97  
Pyrrolizidine (Senecio) alkaloids, toxic actions, 429
- Quinn, R. P. See Makinodan, Santos, and Quinn, 189
- Release, influence on platelet function, 97  
Rerup, Claus C. Drugs producing diabetes through damage of the insulin secreting cells, 485  
Rozengart, E. V. See Kabachnik, Brestkin, Godovikov, Michelson, Rozengart, and Rozengart, 355

- Rozengart, V. I. See Kabachnik, Brestkin, Godovikov, Michelson, Rozengart, and Rozengart, 355
- Rubin, R. P. The role of calcium in the release of neurotransmitter substances and hormones, 389
- Santos, G. W. See Makinodan, Santos, and Quinn, 189
- Senecio, toxic actions of, 429
- Somlyo, A. P. and A. V. Somlyo. Vascular smooth muscle. II. Pharmacology of normal and hypertensive vessels, 249
- Somlyo, A. V. See Somlyo and Somlyo, 249
- Toxic actions of pyrrolizidine (Senecio) alkaloids, 429
- Vascular smooth muscle; pharmacology of normal and hypertensive vessels, 249